Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mahendra Patel, Duncan Richards et al.|The Lancet|2021Cited by 310
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|PLoS ONE|2020Cited by 144
The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trialsBenjamin R. Saville, Scott Berry, Donald A. Berry et al.|Clinical Trials|2022Cited by 72
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational StudyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|medRxiv|2020Cited by 69
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trialChristopher Butler, Ly‐Mee Yu, Mona Bafadhel et al.|medRxiv|2021Cited by 28